» Articles » PMID: 38850129

Healthcare Resource Utilization Among Nursing Home Residents with Parkinson's Disease Psychosis: an Analysis of Medicare Beneficiaries Treated with Pimavanserin or Other-atypical Antipsychotics

Overview
Journal J Comp Eff Res
Specialty Health Services
Date 2024 Jun 8
PMID 38850129
Authors
Affiliations
Soon will be listed here.
Abstract

Real-world healthcare resource use (HCRU) burden among patients with Parkinson's disease psychosis (PDP) treated with pimavanserin (PIM) versus other atypical antipsychotics (other-AAPs) including quetiapine (QUE) in long term care (LTC) and nursing home (NH) settings are lacking. This analysis examines HCRU differences among residents in LTC/NH settings who initiate PIM versus QUE or other-AAPs. A retrospective analysis of LTC/NH residents with PDP from the 100% Medicare claims between 1 April 2015 and 31 December 2021 was conducted. Treatment-naive residents who initiated ≥6 months continuous monotherapy with PIM or QUE or other-AAPs between 04/01/16 and 06/30/2021 were propensity score matched (PSM) 1:1 using 31 variables (age, sex, race, region and 27 Elixhauser comorbidity characteristics). Post-index (i.e., 6 months) HCRU outcomes included: proportion of residents with ≥1 all-cause inpatient (IP) hospitalizations and emergency room (ER) visits. HCRU differences were assessed via log binomial regression and reported as relative risk ratios (RR) and 95% confidence intervals after controlling for dementia, insomnia and index year. From a total of PIM (n = 1827), QUE (n = 7770) or other-AAPs (n = 9557), 1:1 matched sample (n = 1827) in each cohort were selected. All-cause IP hospitalizations (PIM [29.8%]) versus QUE [36.7%]) and ER visits (PIM [47.3%] versus QUE [55.8%]), respectively, were significantly lower for PIM. PIM versus QUE cohort also had significantly lower RR for all-cause IP hospitalizations and ER visits, respectively, (IP hospitalizations RR: 0.82 [0.75. 0.9]; ER visits RR: 0.85 [0.8. 0.9]). PIM versus other-AAPs also had lower likelihood of HCRU outcomes. In this analysis, LTC/NH residents on PIM monotherapy (versus QUE) had a lower likelihood of all-cause hospitalizations (18%) and ER (15%) visits. In this setting, PIM also had lower likelihood of all-cause HCRU versus other-AAPs.

Citing Articles

Global research trends and hotspots in Parkinson's disease psychosis: a 25-year bibliometric and visual analysis.

Wu J, Jin X, Xie W, Liu L, Wang F, Zhu L Front Aging Neurosci. 2024; 16:1480234.

PMID: 39649718 PMC: 11621064. DOI: 10.3389/fnagi.2024.1480234.

References
1.
Alipour-Haris G, Armstrong M, Okun M, Brown J . Comparison of Pimavanserin Versus Quetiapine for Hospitalization and Mortality Risk Among Medicare Beneficiaries with Parkinson's Disease Psychosis. Mov Disord Clin Pract. 2023; 10(3):406-414. PMC: 10026272. DOI: 10.1002/mdc3.13652. View

2.
Nussbaum R, Ellis C . Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003; 348(14):1356-64. DOI: 10.1056/NEJM2003ra020003. View

3.
Goetz C, Fan W, Leurgans S, Bernard B, Stebbins G . The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006; 63(5):713-6. DOI: 10.1001/archneur.63.5.713. View

4.
Diehr P, Yanez D, Ash A, HORNBROOK M, Lin D . Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999; 20:125-44. DOI: 10.1146/annurev.publhealth.20.1.125. View

5.
Rajagopalan K, Rashid N, Doshi D . Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries. J Med Econ. 2023; 26(1):769-776. DOI: 10.1080/13696998.2023.2220597. View